Five things for pharma marketers to know: Monday, November 28, 2016
Photo credit: Open Grid Scheduler / Grid Engine/Creative Commons
1. Johnson & Johnson is in talks with Actelion Pharmaceuticals to acquire the Swiss biotech company, which markets medicines for pulmonary arterial hypertension. Analysts value Actelion at about $26 billion. (Reuters)
2. Novo Nordisk pulled advertising from Breitbart News, the conservative news site founded by Stephen Bannon, chief strategist for President-elect Trump. Many companies reportedly are unaware that their ads are on the site since they invest in larger ad platforms such as Google Ads. (Stat)
3. Takeda Pharmaceuticals received conditional marketing authorization from the European Commission to market Ninlaro for the treatment of multiple myeloma. The drug received FDA approval in November 2015.
4. The House of Representatives is scheduled to vote this week on a revised version of the 21st Century Cures Act. The proposed bill includes funding for President Obama's precision medicine initiative and Vice President Biden's cancer moonshot and $4.8 billion for the National Institutes of Health. (Modern Healthcare)
5. Biogen is scheduled to appear in court over charges from Forward Pharma that it infringed on patents for its multiple-sclerosis drug Tecfidera. Biogen will also likely face further scrutiny when it is expected to release new clinical data on its experimental Alzheimer's drug in December. (Boston Globe)